RxDoctor Payments Data

Nicole Odlum, DO

Family Medicine · Newburgh, INNPI 1669041067

Payments from drug & device makers

$1,415in general payments, 2019–2025

Across 77 payments — averaging $18.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$394
  • AstraZeneca$312
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$216
  • Otsuka America Pharmaceutical, Inc.$107
  • Novo Nordisk$90
  • Axsome Therapeutics, Inc.$64
  • plus $231 from 9 others

What the payments were for

  • Food & beverage$1,415100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,415 in reported general payments places this provider in the 65th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$4,350
Medicare patients
15
Services billed
44

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide15$24,787
JanuviaSitagliptin Phosphate13$14,328
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl21$1,078
Albuterol Sulfate HfaAlbuterol Sulfate26$721
Ventolin HfaAlbuterol Sulfate12$707
Oxcarbazepine12$631
Pregabalin16$493
Levetiracetam14$471
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen17$457
Atorvastatin Calcium62$453
Gabapentin37$447
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen20$346
Aripiprazole20$263
Metformin Hcl ErMetformin Hcl29$260
Omeprazole21$243

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$90$24,78715 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Newburgh

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →